Agalsidase treatment for Fabry disease: Uses and rivalries

Genetics in Medicine

Volumn 12, Issue 11, 2010, Pages 684-685

  Schiffmann, Raphael ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; GLOBOTRIAOSYLCERAMIDE;

DISEASE CLASSIFICATION; FABRY DISEASE; HEART RATE VARIABILITY; HUMAN; NEUROPATHIC PAIN; NOTE; PATIENT SELECTION; QUALITY OF LIFE; QUESTIONNAIRE; SIDE EFFECT; STROKE;

ALPHA-GALACTOSIDASE; FABRY DISEASE; FEMALE; HUMANS; ISOENZYMES; MALE;

EID: 78649631941     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181f9a056     Document Type: Note

References (22)

1. Watt T, Burlina AP, Cazzorla C, et al. Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry registry. Genet Med 2010;12:703-712.
2. Lidove O, West WL, Pintos-Morell G, et al. Effects of enzyme replacement therapy in Fabry disease\a comprehensive review of the medical literature. Genet Med 2010;12:668-679.
3. Mehta A, West WL, Pintos-Morell G, et al. Therapeutic goals in the treatment of Fabry disease. Genet Med 2010;12:713-720.
4. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A\replacement therapy in Fabry's disease. N Eng J Med 2001;345:9-16.
5. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in fabry disease: a randomized controlled trial. JAMA 2001;285:2743-2749.
6. Dreyer NA, Garner S. Registries for robust evidence. JAMA 2009;302:790-791.
7. Gliklich RE, Dreyer NA, editors. Registries for evaluating patient outcomes: a user's guide. (Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Outcome] under Contract No. HHSA29020050035I TO1.) AHRQ Publication No. 07-EHC001-1. Rockville, MD: Agency for Healthcare Research and Quality, 2007.
8. Brown ML, Gersh BJ, Holmes DR, Bailey KR, Sundt TM 3rd. From randomized trials to registry studies: translating data into clinical information. Nat Clin Pract Cardiovasc Med 2008;5:613-620.
9. Stürmer T, Schneeweiss S, Rothman KJ, Avorn J, Glynn RJ. Performance of propensity score calibration\a simulation study. Am J Epidemiol 2007;165: 1110-1118.
10. Stern M, Williams K, Eddy D, Kahn R. Validation of prediction of diabetes by the Archimedes model and comparison with other predicting models. Diabetes Care 2008;31:1670-1671.
11. Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009;374:1986-1996.
12. Schiffmann R, Martin RA, Reimschisel T, et al. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr 2010;156:832-837, 837.e1.
13. Schiffmann R. Fabry disease. Pharmacol Ther 2009;122:65-77.
14. Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 2007;18:2609-2617.
15. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376.
16. Adarkwah CC, Gandjour A. Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany. Int J Technol Assess Health Care 2010;26:62-70.
17. Schiffmann R, Murray GJ, Treco D, et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 2000;97:365-370.
18. Clarke JT, West ML, Bultas J, Schiffmann R. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease. Genet Med 2007;9:504-509.
19. Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009;119:524-529.
20. Schiffmann R, Askari H, Timmons M, et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 2007;18:1576-1583.
21. Murray GJ, Anver MR, Kennedy MA, Quirk JM, Schiffmann R. Cellular and tissue distribution of intravenously administered agalsidase alfa. Mol Genet Metab 2007;90:307-312.
22. Zarate YA, Hopkin RJ. Fabry's disease. Lancet 2008;372:1427-1435.